Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod 15 mg BID vs placebo in frequently exacerbating COPD
2014-002992-27Phase 2Terminated
- Sponsor
- GSK
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Losmapimod 15 mg BID with Placebo (2 arms). Primary endpoint: Yearly rate of moderate and severe COPD exacerbations. Started Sep 2014; status: terminated.
02
Drugs
losmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-002992-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002992-27.